Notice of Proposed Rule Making Affecting Claims That Recite Alternatives 1 Robert Clarke, Director Office of Patent Legal Administration (571) 272-7735.

Slides:



Advertisements
Similar presentations
Technology Center 1600 Training on Writing Rejections Under 35 U.S.C. § 103.
Advertisements

Disclaimer: The information provided by the USPTO is meant as an educational resource only and should not be construed as legal advice or written law.
Incorporation by Reference
INTELLECTUAL PROPERTY PROTECTION OFFICE OF PATENT COUNSEL March 16, 2001.
G & B Seminar 2006 Claim Drafting Ken Moore.
Filing for a United States Patent “Helpful Hints” U.S. Patent and Trademark Office.
More on Restriction Practice Jim Housel SPE, Art Unit 1648 (703)
Notice of Proposed Rule Making Affecting Claims That Recite Alternatives 1 John LeGuyader Director TC1600 Ph:
1 1 1 AIPLA American Intellectual Property Law Association USPTO Updates Including Glossary Pilot Program Chris Fildes Fildes & Outland, P.C. IP Practice.
Julie Burke TC1600 QAS REJOINDER PRACTICE Julie Burke TC1600 QAS
The America Invents Act (AIA) - Rules and Implications of First to File, Prior Art, and Non-obviousness -
September 14, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December.
35 U.S.C. 112, Sixth Paragraph MPEP 2181 – 2186 Jean Witz Quality Assurance Specialist Technology Center 1600.
1 Principles in Restriction Practice TC 1600 Anthony Caputa TC Practice Specialist (571)
Prosecution Group Luncheon Patents August Proposed First-To-File Rules Add definitions in AIA to Rules Declarations for removing references based.
Invention Spotting – Identifying Patentable Inventions Martin Vinsome June 2012.
July 8, Enhanced Examination Timing Control Robert A. Clarke Deputy Director Office of Patent Legal Administration
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
Restriction Practice for Nucleic Acid Molecules Julie Burke QAS/PM
Restriction Practice for Genus Claims Species Claims Linking Claims and Markush Claims Julie Burke QAS/PM TC1600.
Patent Term Adjustment (Bio/Chem. Partnership) Kery Fries, Sr. Legal Advisor Phone: (571)
Patent Overview by Jeff Woller. Why have Patents? Patents make some people rich – but, does that seem like something the government should protect? Do.
1 Standing Committee on the Law of Patents (SCP) A United States Perspective Stephen G. Kunin Deputy Commissioner for Patent Examination Policy United.
Current and Future USPTO Practice RESTRICTION PRACTICES AT THE USPTO 1 © AIPLA 2015.
1 35 U.S.C. § 102(e): The Legislative Fix (S.320) and Serial Abandonment of Provisional Applications Stephen G. Kunin Deputy Commissioner for Patent Examination.
July 18, Changes to Patent Fees Under the Consolidated Appropriations Act, 2005 (H.R. 4818/P.L ) Topic: Patent Fees Office of Patent Legal.
1 United States Patent and Trademark Office Revised PCT International Search and Preliminary Examination Guidelines Biotech/ChemPharm Customer Partnership.
December 8, Changes to Patent Fees Under the Consolidated Appropriations Act, 2005 (H.R. 4818)(upon enactment) and 35 U.S.C. 103(c) as Amended by.
February 19, Recent Changes and Developments in USPTO Practice Prepared by: Office of Patent Legal Administration (OPLA) Robert J. Spar, DirectorJoni.
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
The New USPTO Rules and their Impact on Biomedical Patent Prosecution Mojdeh Bahar, J.D.,M.A. Technology Licensing Specialist Office of Technology Transfer.
35 USC 101 Update Business Methods Partnership Meeting, Spring 2008 by Robert Weinhardt Business Practice Specialist, Technology Center 3600
Contents of US Patent Applications & Filing Requirements
Restriction & Double Patenting Mojdeh Bahar, J.D., M.A., CLP Chief, Cancer Branch Office of Technology Transfer National Institutes of Health U.S. Department.
To Restrict or Not To Restrict That Is The Question? Divided We Stand! Or Undivided We Stand!! By Joseph K. McKane SPE, Art Unit 1626.
1 Restriction Practice Updates Julie Burke TC1600 Quality Assurance Specialist
35 U.S.C. 112, Second Paragraph Examination Memorandum Robert Clarke Director, Office of Patent Legal Administration United States Patent and Trademark.
July 18, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December 10,
Election of Species Joseph K. McKane SPE, Art Unit 1626 April 27, 2004.
Securing Innovation Michael D. Stein Stein, McEwen & Bui LLP 1400 Eye Street, NW Suite 300 Washington, DC (202)
Hamre, Schumann, Mueller & Larson, P.C U.S. Patent Claims By James A. Larson.
1 When is it NOT Appropriate to Restrict? Julie Burke TC1600 QAS
Claims and Continuations Final Rule Overview Briefing for Examiners 1.
New Sections 102 & 103 (b) Conditions for Patentability- (1) IN GENERAL- Section 102 of title 35, United States Code, is amended to read as follows: -`Sec.
Revoking Consent for Special Education Services COSA Fall Special Education Conference October 2009 Rae Ann Ray Office of Student Learning & Partnerships.
New Ex Parte Appeal Rules Patent and Trademark Practice Group Meeting January 26, 2012.
Trilateral Project WM4 Report on comparative study on Examination Practice Relating to Single Nucleotide Polymorphisms (SNPs) and Haplotypes. Linda S.
Claims and Continuations Final Rule 1 Joni Y. Chang Senior Legal Advisor Office of Patent Legal Administration (571) ,
FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice Julie Burke TC1600 Quality Assurance Specialist
1 Restriction Petition Survey; A Few Helpful Hints Julie Burke TC1600 Special Program Examiner
1 1 1 AIPLA Firm Logo American Intellectual Property Law Association U.S. Implementation of the Hague Agreement For Designs John (Jack) J. Penny, V Event.
Chris Fildes FILDES & OUTLAND, P.C. IP Practice in Japan Committee Pre-Meeting AIPLA Annual Meeting, October 20, 2015 USPTO PILOT PROGRAMS 1 © AIPLA 2015.
James Toupin – General Counsel February 1, Summary of Proposed Rule Changes to Continuations, Double Patenting, and Claims.
Claims Proposed Rulemaking Main Purposes É Applicant Assistance to Improve Focus of Examination n Narrow scope of initial examination so the examiner is.
Derivation Proceedings Gene Quinn Patent Attorney IPWatchdog.com March 27 th, 2012.
January 25, Notice of Proposed Rule Making Proposed Changes to Practice for Continuing Applications, Requests for Continued Examination Practice,
Double Patenting Deborah Reynolds SPE Art Unit 1632 Detailee, TC1600 Practice Specialist
1 Biotech/Chem/Pharm Customer Partnership Meeting June 15, 2005 USPTO Study on Restriction Reform and Update on TC1600 Restriction Practice Action Plan.
June 13, Biotechnology/Chemical/Pharmaceutical Customer Partnership USPTO Study on Restriction Reform and TC1600 Restriction Practice Action Plan.
Bruce Kisliuk Group Director, Technology Center 1600.
The Impact of Patent Reform on Independent Inventors and Start-up Companies Mark Nowotarski (Patent Agent)
1 FY08 Restriction Petition Update and Burden Julie Burke Quality Assurance Specialist Technology Center 1600.
Intellectual Property And Data Rights Issues Domestic & Global Perspectives Bayh-Dole act -- rights in data Henry N. Wixon Chief Counsel National Institute.
PATENT OFFICE PROSECUTION
Tim Saulsbury -- Continuations in Part
Claims and Continuations Final Rule
PATENT LAW TREATY Gena Jones Senior Legal Advisor
The Rulemaking Process
Ram R. Shukla, Ph.D. SPE AU 1632 & 1634 Technology Center
Subject Matter Eligibility
Presentation transcript:

Notice of Proposed Rule Making Affecting Claims That Recite Alternatives 1 Robert Clarke, Director Office of Patent Legal Administration (571)

Notice of Proposed Rule Making “ Examination of Patent Applications that Include Claims Containing Alternative Language” published in the Federal Register Vol. 72 No August 2007 – 60 day public comment period 2

Proposed Rule Changes 60 day comment period ended October 9, comments received Posted on pla/comments/markush/markush.html 3

Proposed Rule Changes Would Apply to All Claims that Use Alternative Language An alternative claim is any claim that lists alternatives, including “Markush” claims. Alternatives are commonly listed as: –selected from the group consisting of A, B and C –wherein the X is a A, B or C. example: wherein the fastener is a nail, screw or adhesive 4

5 Current Practice for Claims Using Alternative Language Currently there is no explicit guidance for restricting among independent and distinct inventions when claimed as alternatives in a single claim. “Markush” practice permits the examiner to require a provisional election of species. If the elected species is found allowable, the examiner must extend the search and examination to the extent necessary to determine patentability of the claim, even if the claim lists independent and distinct inventions. MPEP §

The Proposal for Claims Using Alternative Language In an effort to level the playing field for all and provide for a more efficient, thorough and quality examination, the Office is considering requiring those applicants who chose to draft claims that recite alternatives or species to maintain a certain degree of relatedness among the alternatives. 72 Fed. Reg

Overview of Proposed Rule Changes 7 1)A claim must be limited to a single invention. 1.75(a) and 1.140(a) 2)Intra-claim restriction will be permitted when a claim is not limited to a single invention (a) and 1.142(b) 3)Applicants may file a statement explaining how their claim is limited to a single invention (b) 4) A claim using alternative language must be in the proper format. 1.75(j) 5)Claims should be self-contained. 1.75(k) 6)Claims listing non-elected inventions will be subject to objection (d) 7)Applicants must identify the effective priority date for each claim that seeks the benefit of a prior filed application. 1.75(d)(2)

An alternative-type claim is limited to a single invention when either: (i)The alternatives share a substantial feature essential for a common utility, OR (ii) The alternatives are prima facie obvious over each other. 1.75(a) and 1.140(a) 1)A claim must be limited to a single invention. 8

The propriety of a requirement for restriction shall be determined without regard to whether the plural inventions are recited in separate claims or as alternatives within a single claim (a) and 1.142(b) 2) Intra-claim restriction will be be permitted when a claim is not limited to a single invention. 9

The presentation of an alternative claim may be accompanied by a statement explaining why the claim is limited to a single invention if the statement is filed at the time of presentation of the claim or prior to the mailing of a restriction or action on the merits (b) 10 3) Applicants may file a statement explaining how their claim is limited to a single invention.

Objectionable Claim Formats: (i)The number and presentation of alternatives in a single claim must not make the claim difficult to construe. 1.75(j)(1) (ii)No alternative may itself be defined as a set of further alternatives within the claim. 1.75(j)(2) (iii)No alternative can be encompassed by any other alternative within a list of alternatives unless there is no other practical way to define the invention. 1.75(j)(3) (iv)All alternatives must be substitutable one for another. 1.75(j)(4) 4)A claim using alternative language must be in the proper format. 11

(i) A claim cannot incorporate a set of alternatives by reference to the specification or drawings unless there is no other practical way to define the invention. For example: Claim 1. A compound selected from Table 1. (where Table 1 lists the formulas for 100 separate compounds) (ii) If a claim incorporates alternatives by reference to the specification, that claim will be treated as an alternative claim. 1.75(k) 5)Claims should be self-contained. 12

(i)Any claim limited solely to a non-elected invention, if not canceled, is withdrawn from further consideration. (ii)Any claim that recites both elected and non-elected inventions will be subjected to an objection. (iii)Non-elected subject matter must be canceled from a claim before the claim is allowed. For Applications under 35 U.S.C. 111(a) – see 1.142(c) and (d) For National Stage Applications- see 1.499(b) and (c) 6)Treatment of claims listing non-elected inventions. 13

7) Applicants must identify the effective priority date for each claim that seeks the benefit of a prior filed application. 14 If an application seeks the benefit under title 35, United States Code of a prior-filed application and discloses subject matter that was not disclosed in the prior-filed application, the applicant must identify which claim or claims in the application are disclosed in the manner provided by the first paragraph of 35 U.S.C. 112 in the prior-filed application. 1.75(d)(2)

More on Intra-Claim Restriction The proposed rule changes are intended to: –Limit each claim to a single invention. –Permit RESTRICTION within a single claim listing alternatives if the alternatives are not directed to a single invention: When the alternatives do not share a substantial feature essential for a common utility or are not obvious variants over each other. Standard “Markush” practice (election of species) would remain an option where the alternatives share a substantial feature essential for a common utility. MPEP §

To Identify Substantial Feature Essential for Common Utility The Markush claim must be considered as a whole. The “feature” must be shared by all of the alternatives and is typically –A Structure for Products or –An Active Step for Processes. “Substantial” means a feature that –Specifically contributes towards the common utility or –Provides the same effect among the alternatives. The “common utility” is derived from the essential substantial feature and results in the same effect for every alternative –The common utility must meet the requirements of 35 U.S.C. 101, (e.g., be specific, substantial and credible). 16

17 Thank you Robert Clarke, Director Office of Patent Legal Administration (571)